Skip to main content
Premium Trial:

Request an Annual Quote

All Personal

The drug pipelines of pharmaceutical companies like AstraZeneca are full of therapeutics being developed for personalized medicine, writes Frank Vinluan at MedCity News. AstraZeneca's Steve Labkoff says that 65 percent of the company's pipeline is personalized medicine. Vinluan adds that a common theme at the SAS Health Care and Life Sciences Executive Conference last week, where Labkoff was a speaker, was that "big data healthcare information is on its way to consumers" and that it will extend beyond medicine to insurance.

"Analysis of patient data from [Blue Cross Blue Shield North Carolina] will enable the company to develop plans tailored to customers," Vinluan writes, adding that big data is "already helping to develop pharmaceuticals personalized to patients. And soon their healthcare plans will become personalized, too."

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.